Johnson & Johnson and 4 Other Biopharmaceutical Stocks That Might Be Ready to Break Out
Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...
Bank of America Securities Remains a Buy on Gilead Sciences (GILD)
In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Gilead Sciences (GILD – Research Report), ...
Wells Fargo Reaffirms Their Buy Rating on Gilead Sciences (GILD)
Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $140.00.
Shaping the future of healthcare analytics: Nidhi Shashikumar's data-driven Impact
With over seven years of experience in data science and analytics, Nidhi has led high-impact projects at leading healthcare ...
Oppenheimer Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price
Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report released on Tuesday, Marketbeat reports. Oppenheimer currently has an ...